Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer’s disease

See Schott and Fox (doi: 10.1093/brain/awv405 ) for a scientific commentary on this article. The relationships between pathophysiological processes in Alzheimer’s disease remain largely unclear. In a longitudinal, multitracer PET study, Rodriguez-Vieitez et al. reveal that progression of autosomal dominant Alzheimer’s disease is accompanied by prominent early and then declining astrocytosis, increasing amyloid plaque deposition and decreasing glucose metabolism. Astrocyte activation may initiate Alzheimer pathology.

• Publication year

  2016

• Venue

  Brain : a journal of neurology

• Publication date

  2016-01-26

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1093/brain/awv404PMID 26813969PMCID 4766380
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Astrocytes in physiological aging and Alzheimer's disease.

  2016cited by this paper
• Imaging neuroinflammation in Alzheimer’s and other dementias: recent advances and future directions

  2016cited by this paper
• Evolving brain structural changes in PSEN1 mutation carriers.

  2015cited by this paper
• Multiple amyloid binding sites in Alzheimer brain and their interaction with synaptic and inflammatory mechanisms

  2015cited by this paper
• Early astrocytosis in autosomal dominant Alzheimer’s disease measured in vivo by multi-tracer positron emission tomography

  2015influential reference
• Glial Asthenia and Functional Paralysis

  2015cited by this paper
• Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study.

  2015cited by this paper
• Brain Imaging and Blood Biomarker Abnormalities in Children With Autosomal Dominant Alzheimer Disease: A Cross-Sectional Study.

  2015cited by this paper
• Neuroinflammation in Alzheimer's disease.

  2015cited by this paper
• Innate immunity in Alzheimer's disease

  2015cited by this paper
• Imaging neuroinflammation in Alzheimer's disease and other dementias: Recent advances and future directions

  2015cited by this paper
• Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study.

  2015cited by this paper
• Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study

  2015cited by this paper
• Astrocytosis measured by 11C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer’s patients

  2014cited by this paper
• Genetic Heterogeneity in Alzheimer Disease and Implications for Treatment Strategies

  2014influential reference
• The value of biomarker comparisons between autosomal dominant and late-onset Alzheimer disease.

  2014cited by this paper
• Functional connectivity in autosomal dominant and late-onset Alzheimer disease.

  2014cited by this paper
• Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.

  2014cited by this paper
• Characterizing the normative profile of 18F-FDG PET brain imaging: sex difference, aging effect, and cognitive reserve.

  2014cited by this paper
• Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer's disease.

  2014influential reference
• Preclinical Cerebrospinal Fluid and Volumetric Magnetic Resonance Imaging Biomarkers in Swedish Familial Alzheimer's Disease

  2014cited by this paper
• Tracking neuroinflammation in Alzheimer’s disease: the role of positron emission tomography imaging

  2014cited by this paper
• Heterogeneity of reactive astrocytes.

  2014cited by this paper
• Symptom onset in autosomal dominant Alzheimer disease

  2014cited by this paper
• Biomarker modeling of Alzheimer's disease.

  2013cited by this paper
• Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.

  2013cited by this paper
• Increased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation Carriers

  2013influential reference
• 3H-Deprenyl and 3H-PIB autoradiography show different laminar distributions of astroglia and fibrillar β-amyloid in Alzheimer brain

  2013cited by this paper
• Reply: Implications of presymptomatic change in thalamus and caudate in Alzheimer’s disease

  2013cited by this paper
• Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease

  2013influential reference
• Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimer’s disease

  2013cited by this paper
• Alzheimer disease: Aβ-independent processes—rethinking preclinical AD

  2013cited by this paper
• Clinical and biomarker changes in dominantly inherited Alzheimer's disease.

  2012cited by this paper
• Targeting Astrocytes Ameliorates Neurologic Changes in a Mouse Model of Alzheimer's Disease

  2012cited by this paper
• A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease

  2012influential reference
• Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study.

  2012cited by this paper
• Region-Specific Hierarchy between Atrophy, Hypometabolism, and β-Amyloid (Aβ) Load in Alzheimer's Disease Dementia

  2012cited by this paper
• The effect of amyloid associated proteins on the expression of genes involved in amyloid-β clearance by adult human astrocytes.

  2012influential reference
• Noninvasive molecular imaging of neuroinflammation

  2012cited by this paper
• Heterogeneity of astrocytic form and function.

  2012cited by this paper
• Evidence for Astrocytosis in Prodromal Alzheimer Disease Provided by 11C-Deuterium-L-Deprenyl: A Multitracer PET Paradigm Combining 11C-Pittsburgh Compound B and 18F-FDG

  2012influential reference
• The role of astrocytes in amyloid β-protein toxicity and clearance.

  2012cited by this paper
• Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers

  2012cited by this paper
• Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation.

  2011cited by this paper
• Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

  2011influential reference
• Time Course of Glucose Metabolism in Relation to Cognitive Performance and Postmortem Neuropathology in Met146Val PSEN1 Mutation Carriers

  2011cited by this paper
• Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease

  2011cited by this paper
• In vivo imaging of astrocytosis in Alzheimer’s disease: an 11C-L-deuteriodeprenyl and PIB PET study

  2011cited by this paper
• Alzheimer’s Disease: The Challenge of the Second Century

  2011cited by this paper
• Alzheimer's disease.

  2011cited by this paper
• Imaging of neuroinflammation

  2011cited by this paper
• Amyloid-dependent and amyloid-independent stages of Alzheimer disease.

  2011cited by this paper
• Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography.

  2011cited by this paper
• Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders

  2011cited by this paper
• Increased Cortical Thickness and Caudate Volume Precede Atrophy in PSEN1 Mutation Carriers

  2010cited by this paper
• Astrocyte heterogeneity: an underappreciated topic in neurobiology.

  2010cited by this paper
• Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer’s disease

  2010cited by this paper
• Alzheimer disease.

  2010cited by this paper
• P4‐070: Higher Amyloid Burden is Associated With Decreased Hippocampal and Parahippocampal Activation Across Two Functional Tasks in Healthy Older Adults

  2010cited by this paper
• Amyloid-β Aggregates Cause Alterations of Astrocytic Metabolic Phenotype: Impact on Neuronal Viability

  2010cited by this paper
• The PSEN1 I143T mutation in a Swedish family with Alzheimer's disease: clinical report and quantification of Aβ in different brain regions

  2010cited by this paper
• High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types.

  2009cited by this paper
• Activated astrocytes: a therapeutic target in Alzheimer’s disease?

  2009cited by this paper
• PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease.

  2008cited by this paper
• The mystery and magic of glia: a perspective on their roles in health and disease.

  2008cited by this paper
• Amyloid Deposition Begins in the Striatum of Presenilin-1 Mutation Carriers from Two Unrelated Pedigrees

  2007cited by this paper
• Evidence for astrocytosis in ALS demonstrated by [11C](L)-deprenyl-D2 PET.

  2007cited by this paper
• Translational Neuroimaging: Positron Emission Tomography Studies of Monoamine Oxidase

  2005cited by this paper
• Neuroscience. The dark side of glia.

  2005cited by this paper
• High selective expression of alpha7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer's disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques.

  2005cited by this paper
• The Dark Side of Glia

  2005cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004cited by this paper
• Mild cognitive impairment as a diagnostic entity

  2004influential reference
• Three‐dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe

  2003cited by this paper
• Estimation of the number of "true" null hypotheses in multivariate analysis of neuroimaging data.

  2001influential reference
• Amyloid-beta 25-35 peptide induces expression of monoamine oxidase B in cultured rat astrocytes.

  2000cited by this paper
• Preserved Pontine Glucose Metabolism in Alzheimer Disease: A Reference Region for Functional Brain Image (PET) Analysis

  1995cited by this paper
• Controlling the false discovery rate: a practical and powerful approach to multiple testing

  1995influential reference
• Evidence for apoptotic cell death in Alzheimer's disease.

  1995cited by this paper
• Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography.

  1994cited by this paper
• Monoamine oxidase‐B in astrocytes

  1993cited by this paper
• Alzheimer's disease: the amyloid cascade hypothesis.

  1992cited by this paper
• Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET.

  1987influential reference
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• Multiple Comparisons Using Rank Sums

  1964cited by this paper

• Non-invasive modelling and parametric methods for quantification of MAO-B activity using [11C]L-deprenyl-D2 PET.

  2026cites this paper
• Enhancing diagnosis of mild cognitive impairment through brain-heart-gut metabolic networks in whole-body PET imaging.

  2026cites this paper
• Early functional changes and plasma GFAP in Swedish families with Autosomal Dominant Alzheimer’s disease mutations

  2026influential citation
• Stage-Dependent Function of Astrocytes in Alzheimer's Disease: A Review.

  2026cites this paper
• PET imaging of TREM2 in amyloid-beta induced neuroinflammation

  2025cites this paper
• MAO-B status in alcohol use disorder: a [11C]SL25.1188 PET imaging study of putative astrogliosis.

  2025cites this paper
• Impact of Redox Imbalance and Mitochondrial Dysfunction on Neurotoxicity Induced by Perfluorooctanoic Acid in Male Wistar Albino Rats (Rattus norvegicus).

  2025cites this paper
• GADD45G operates as a pathological sensor orchestrating reactive gliosis and neurodegeneration.

  2025cites this paper
• Mapping reactive astrogliosis in Parkinson's brain with astroglial tracers BU99008 and Deprenyl: New insights from a multi‐marker postmortem study

  2025cites this paper
• Noradrenergic system in the pathogenesis of age-dependent neurodegeneration

  2025cites this paper
• IND-Enabling Preclinical Studies of [11C]COU, a Trapped Metabolite PET Radiotracer for Monoamine Oxidase-B

  2025cites this paper
• Neuroinflammation in neurodegenerative diseases: Focusing on the mediation of T lymphocytes

  2025cites this paper
• The Role of Neuroglia in Cognitive Longevity

  2025cites this paper
• IND-enabling preclinical studies of [11C]COU, a trapped metabolite PET radiotracer for monoamine oxidase-B

  2025cites this paper
• Advances in Gene Therapy for Neurologic Disorders: An Overview

  2025cites this paper
• Peripheral Inflammation Is Associated With Greater Neuronal Injury and Lower Episodic Memory Among Late Middle‐Aged Adults

  2025cites this paper
• Noradrenergic excitation of astrocytes supports cognitive reserve

  2025cites this paper
• Quantification of monoamine oxidase B expression with 11C-SL25.1188 for imaging reactive astrocytes in patients with Alzheimer’s disease

  2025cites this paper
• DYRK1A in the physiology and pathology of the neuron-astrocyte axis

  2025cites this paper
• Early microglial and astrocyte reactivity in preclinical Alzheimer's disease

  2025cites this paper
• Early astrocyte-targeted intervention guided by 18F-SMBT-1 imaging attenuates disease progression in 3xTg-AD mice

  2025influential citation
• Risk of dementia in older patients with different anesthesia: a systematic review and meta-analysis of cohort studies

  2025cites this paper
• Astrocytes as Metabolic Sensors Orchestrating Energy‐Driven Brain Vulnerability in Alzheimer's Disease

  2025cites this paper
• Proteome-wide analysis identifies plasma immune regulators of amyloid-beta progression.

  2024cites this paper
• PET imaging of neuroinflammation: any credible alternatives to TSPO yet?

  2024cites this paper
• Patterns of longitudinal subcortical atrophy over one year in amnestic mild cognitive impairment and its impact on cognitive performance: a preliminary study

  2024cites this paper
• A Key Mediator and Imaging Target in Alzheimer’s Disease: Unlocking the Role of Reactive Astrogliosis Through MAOB

  2024cites this paper
• Decreased extrasynaptic δ‐GABAA receptors in PNN‐associated parvalbumin interneurons correlates with anxiety in APP and tau mouse models of Alzheimer's disease

  2024cites this paper
• Directed Functional Connectivity Changes of Triple Networks for Stable and Progressive Mild Cognitive Impairment.

  2024cites this paper
• Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach.

  2024cites this paper
• PET Imaging to Measure Neuroinflammation In Vivo.

  2024cites this paper
• Bioinformatic identification and experiment validation reveal 6 hub genes, promising diagnostic and therapeutic targets for Alzheimer’s disease

  2024cites this paper
• Relationship Between Reactive Astrocytes, by [18F]SMBT-1 Imaging, with Amyloid-Beta, Tau, Glucose Metabolism, and TSPO in Mouse Models of Alzheimer’s Disease

  2024cites this paper
• Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer’s disease

  2024cites this paper
• Plasma glial fibrillary acidic protein in the visual and language variants of Alzheimer's disease

  2024cites this paper
• A phase 2, open-label study of anti-inflammatory NE3107 in patients with dementias

  2024cites this paper
• Monoamine oxidase and neurodegeneration: mechanisms, inhibitors and natural compounds for therapeutic intervention.

  2024cites this paper
• Brain energy metabolism: A roadmap for future research

  2024cites this paper
• Lipidomic Analysis Reveals Biomarkers for Alzheimer's Disease

  2023cites this paper
• Molecular Imaging of Neuroinflammation in Alzheimer's Disease and Mild Cognitive Impairment.

  2023cites this paper
• The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease

  2023cites this paper
• Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer’s Disease

  2023cites this paper
• Neutrophils as a potential therapeutic target in Alzheimer’s disease

  2023cites this paper
• Plasma and cerebrospinal fluid glial fibrillary acidic protein levels in adults with Down syndrome: a longitudinal cohort study.

  2023cites this paper
• Early mitochondrial dysfunction proceeds neuroinflammation, synaptic alteration, and autophagy impairment in hippocampus of App knock-in Alzheimer mouse models

  2023cites this paper
• Milestone Review: Metabolic dynamics of glutamate and GABA mediated neurotransmission — The essential roles of astrocytes

  2023cites this paper
• Development of Computational Correlations among Known Drug Scaffolds and their Target-Specific Non-Coding RNA Scaffolds of Alzheimer's Disease.

  2023cites this paper
• Second Wave, Late-Stage Neuroinflammation in Cleared Brains of Aged 5xFAD Alzheimer’s Mice Detected by Macrolaser Light Sheet Microscopy Imaging

  2023cites this paper
• [18F]F-DED PET imaging of reactive astrogliosis in neurodegenerative diseases: preclinical proof of concept and first-in-human data

  2023cites this paper
• Multitracer Approach to Understanding the Complexity of Reactive Astrogliosis in Alzheimer’s Brains

  2023cites this paper
• Proteomics of the astrocyte secretome reveals changes in their response to soluble oligomeric Aß

  2023cites this paper
• Astrocyte biomarkers GFAP and YKL‐40 mediate early Alzheimer's disease progression

  2023cites this paper
• Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP

  2023influential citation
• Multimodality imaging of neurodegenerative disorders with a focus on multiparametric magnetic resonance and molecular imaging

  2023cites this paper
• Longitudinal amyloid and tau PET imaging in Alzheimer's disease: A systematic review of methodologies and factors affecting quantification

  2023cites this paper
• Relationship between reactive astrocytes, by [18F]SMBT-1 imaging, with amyloid-beta, tau, glucose metabolism, and microgliosis in mouse models of Alzheimer’s disease

  2023cites this paper
• Astrocyte Signature in Alzheimer’s Disease Continuum through a Multi-PET Tracer Imaging Perspective

  2023cites this paper
• GFAP as a Potential Biomarker for Alzheimer’s Disease: A Systematic Review and Meta-Analysis

  2023cites this paper
• Neuroinflammation Biomarkers in the AT(N) Framework Across the Alzheimer’s Disease Continuum

  2023cites this paper
• Advanced brain imaging for the diagnosis of Alzheimer disease

  2023cites this paper
• Proteomics of the astrocyte secretome reveals changes in their response to soluble oligomeric Aβ

  2023cites this paper
• Adrenergic regulation of astroglial aerobic glycolysis and lipid metabolism: Towards a noradrenergic hypothesis of neurodegeneration.

  2023cites this paper
• Imaging of Reactive Astrogliosis by Positron Emission Tomography

  2022cites this paper
• Microglia and Astrocyte Function and Communication: What Do We Know in Humans?

  2022cites this paper
• Clear‐headed into old age: Resilience and resistance against brain aging—A PET imaging perspective

  2022cites this paper
• Cognitive Impairment in Heart Failure: Landscape, Challenges, and Future Directions

  2022cites this paper
• Assessing Reactive Astrogliosis with 18F-SMBT-1 Across the Alzheimer Disease Spectrum

  2022cites this paper
• Positron Emission Tomography in Animal Models of Tauopathies

  2022cites this paper
• Presubiculum principal cells are preserved from degeneration in knock-in APP/TAU mouse models of Alzheimer’s disease

  2022cites this paper
• First-in-Humans Evaluation of 18F-SMBT-1, a Novel 18F-Labeled Monoamine Oxidase-B PET Tracer for Imaging Reactive Astrogliosis

  2022cites this paper
• Low-dose brain irradiation normalizes TSPO and CLUSTERIN levels and promotes the non-amyloidogenic pathway in pre-symptomatic TgF344-AD rats

  2022cites this paper
• Towards Astroglia-based Noradrenergic Hypothesis of Alzheimer’s Disease

  2022cites this paper
• Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: Associations with Aβ‐PET, neurodegeneration, and cognition

  2022cites this paper
• Association of longitudinal cognitive decline with diffusion MRI in Gray Matter, Amyloid, and Tau deposition.

  2022cites this paper
• Acidic oligosaccharide sugar chain combined with hyperbaric oxygen delays D-galactose-induced brain senescence in mice via attenuating oxidative stress and neuroinflammation.

  2022cites this paper
• Herpes Viruses in the Baltimore Longitudinal Study of Aging

  2022cites this paper
• Supervised Deep Learning for Head Motion Correction in PET

  2022cites this paper
• Functionalization of Radiolabeled Antibodies to Enhance Peripheral Clearance for High Contrast Brain Imaging

  2022cites this paper
• Early loss of locus coeruleus innervation promotes cognitive and neuropathological changes before amyloid plaque deposition in a transgenic rat model of Alzheimer's disease

  2022cites this paper
• In Alzheimer's disease, amyloid beta accumulation is a protective mechanism that ultimately fails

  2022cites this paper
• Isolation and characterization of neurotoxic astrocytes derived from adult triple transgenic Alzheimer's disease mice.

  2022cites this paper
• Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer’s continuum

  2022cites this paper
• Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer’s Disease and Other Tauopathies

  2022cites this paper
• Alzheimer’s Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint

  2022cites this paper
• Monoamine oxidase binding not expected to significantly affect [18F]flortaucipir PET interpretation

  2022cites this paper
• Astrogliosis in aging and Parkinson’s disease dementia: a new clinical study with 11C-BU99008 PET

  2022cites this paper
• Astrocyte energy and neurotransmitter metabolism in Alzheimer's disease: integration of the glutamate/GABA-glutamine cycle.

  2022cites this paper
• INTERESTERIFIED FAT MATERNAL CONSUMPTION BEFORE CONCEPTION PROGRAMMS MEMORY AND LEARNING OF ADULTHOOD OFFSPRING: how big is this deleterious repercussion?

  2022cites this paper
• Mapping cerebral atrophic trajectory from amnestic mild cognitive impairment to Alzheimer's disease.

  2022cites this paper
• AAV Vector-Mediated Antibody Delivery (A-MAD) in the Central Nervous System

  2022cites this paper
• Glial Cells in Alzheimer's Disease: From Neuropathological Changes to Therapeutic Implications.

  2022cites this paper
• Cerebrospinal Fluid Pro le of Lipid Mediators In Alzheimer’s Disease

  2021cites this paper
• Cerebrospinal Fluid Profile of Lipid Mediators in Alzheimer’s Disease

  2021cites this paper
• Reactive astrogliosis: A friend or foe in the pathogenesis of Alzheimer’s disease

  2021cites this paper
• Can Ketogenic Diet Improve Alzheimer's Disease? Association With Anxiety, Depression, and Glutamate System

  2021cites this paper
• Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer’s disease: findings from the Colombia-Boston (COLBOS) biomarker study

  2021cites this paper
• Genetic Therapies for Alzheimer’s Disease: A Scoping Review

  2021cites this paper
• Cortical thickness is differently associated with ALDH2 rs671 polymorphism according to level of amyloid deposition

  2021cites this paper
• The Implication of Glial Metabotropic Glutamate Receptors in Alzheimer’s Disease

  2021cites this paper
• Cognitive Dysfunction after Heart Disease: A Manifestation of the Heart-Brain Axis

  2021cites this paper